ArticleAbdominal radiology (New York)2026
Clinical and LI-RADS features on gadoxetic acid‑enhanced MRI for predicting complete response after transarterial chemoembolization in hepatocellular carcinoma > 2 cm.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTransarterial chemoembolization (TACE) is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC), but the rate of complete response (CR) after TACE varies widely. Pretreatment identification of patients likely to achieve CR remains clinically challenging. PURPOSE: To assess the pretreatment predictive value of liver imaging reporting and data system (LI-RADS) features and clinical features on gadoxetic acid-enhanced MRI (EOB-MRI) for CR after TACE in patients with HCC > 2 cm.
methodsFrom June 2018 to June 2025, 167 patients with unresectable HCC were enrolled in this retrospective single-center study. All patients underwent EOB-MRI within 2 weeks before initial TACE. Treatment response was classified as CR or non-complete response (nCR) using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Clinical and MRI features associated with CR were identified using univariate and multivariate logistic regression analyses. The area under the receiver operating characteristic curve (AUC) was used to assess the model performance.
resultsA total of 61 of the 167 patients (36.5%) achieved CR on follow-up imaging at 3-4 months after TACE. Multivariate analysis revealed that tumor diameter (odds ratio [OR]: 0.965, 95% confidence interval [CI]: 0.943-0.987; p = 0.002), irregular border (OR: 0.404, 95% CI: 0.196-0.832; p = 0.014), and enhancing capsule (OR: 3.006, 95% CI: 1.147-7.877; p = 0.025) were significantly associated with CR. The combined model incorporating these three features yielded an AUC of 0.723 (95% CI: 0.649-0.790, p < 0.0001), outperforming that of each individual predictor (AUC = 0.658, 0.615, and 0.565, respectively).
conclusionsA simple imaging-based model incorporating tumor diameter, irregular border, and enhancing capsule achieved moderate performance for predicting CR after TACE in patients with HCC > 2 cm, and may serve as a practical tool for response stratification and individualized treatment decisions.
Indexed as
Identifiers
42406033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.